HomeCompareKARBF vs VIG

KARBF vs VIG: Dividend Comparison 2026

KARBF yields 38.10% · VIG yields 1.64%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 KARBF wins by $176.5K in total portfolio value
10 years
KARBF
KARBF
● Live price
38.10%
Share price
$5.25
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$208.9K
Annual income
$33,891.10
Full KARBF calculator →
VIG
Vanguard Dividend Appreciation ETF
● Live price
1.64%
Share price
$210.70
Annual div
$3.45
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$32.4K
Annual income
$179.15
Full VIG calculator →

Portfolio growth — KARBF vs VIG

📍 KARBF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodKARBFVIG
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, KARBF + VIG cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
KARBF pays
VIG pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

KARBF
Annual income on $10K today (after 15% tax)
$3,238.10/yr
After 10yr DRIP, annual income (after tax)
$28,807.43/yr
VIG
Annual income on $10K today (after 15% tax)
$139.33/yr
After 10yr DRIP, annual income (after tax)
$152.28/yr
At 15% tax rate, KARBF beats the other by $28,655.16/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of KARBF + VIG for your $10,000?

KARBF: 50%VIG: 50%
100% VIG50/50100% KARBF
Portfolio after 10yr
$120.6K
Annual income
$17,035.13/yr
Blended yield
14.12%
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

KARBF buys
0
VIG buys
0
No recent congressional trades found for KARBF or VIG in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricKARBFVIG
Forward yield38.10%1.64%
Annual dividend / share$2.00$3.45
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%0%
Portfolio after 10y$208.9K$32.4K
Annual income after 10y$33,891.10$179.15
Total dividends collected$154.9K$1.7K
Payment frequencyquarterlyquarterly
SectorStockETF

Year-by-year: KARBF vs VIG ($10,000, DRIP)

YearKARBF PortfolioKARBF Income/yrVIG PortfolioVIG Income/yrGap
1← crossover$14,510$3,809.52$11,304$163.92+$3.2KKARBF
2$20,691$5,165.83$12,759$166.33+$7.9KKARBF
3$29,024$6,884.70$14,382$168.52+$14.6KKARBF
4$40,081$9,025.64$16,192$170.52+$23.9KKARBF
5$54,536$11,648.73$18,210$172.34+$36.3KKARBF
6$73,166$14,812.69$20,460$173.98+$52.7KKARBF
7$96,860$18,572.81$22,968$175.48+$73.9KKARBF
8$126,620$22,978.99$25,763$176.83+$100.9KKARBF
9$163,557$28,073.84$28,878$178.05+$134.7KKARBF
10$208,897$33,891.10$32,350$179.15+$176.5KKARBF

KARBF vs VIG: Complete Analysis 2026

KARBFStock

Karo Pharma AB (publ) develops and markets prescription drugs and over-the-counter products for pharmacies and retail sector in Sweden, Norway, Denmark, Finland, France, Germany, Italy, rest of Europe, the United States, and internationally. It offers skin health products under the Remescar, Locobase, Decubal, and indy beauty brand names; intimate health products under the Pevaryl, Multi Gyn, Asan, and Selexid brand names; and foot health products under the Pevaryl, CCS, Nailner, and wortie brands. The company also provides pain, cough, and cold products under the Paracet, Ibux, Mollipect, and Viruseptin brand names; prescription drugs under the Burinex, Centyl, Kaleorid, and Lithionit brands; and wellness products under the nutravita, Alpha Foods, Flux, Allévo, Dosett, Dax, and Lactocare brands. It sells its products in approximately 90 countries with Europe and the Nordic region markets through direct sales organizations and a network of distributors, as well as online. The company was formerly known as Karo Bio AB (publ) and changed its name to Karo Pharma AB (publ) in March 2016. Karo Pharma AB (publ) was incorporated in 1987 and is headquartered in Stockholm, Sweden.

Full KARBF Calculator →

VIGETF

Seeks to track the performance of the S&P U.S. Dividend Growers Index.Passively managed, full-replication approach.Fund remains fully invested.Large-cap equity, emphasizing stocks with a record of growing their dividends year over year.Low expenses minimize net tracking error.With respect to 75% of its total assets, the fund may not: (1) purchase more than 10% of the outstanding voting securities of any one issuer or (2) purchase securities of any issuer if, as a result, more than 5% of the fund’s total assets would be invested in that issuer’s securities; except as may be necessary to approximate the composition of its target index. This limitation does not apply to obligations of the U.S. government or its agencies or instrumentalities.

Full VIG Calculator →
📬

Get this KARBF vs VIG comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

KARBF vs SCHDKARBF vs JEPIKARBF vs OKARBF vs KOKARBF vs MAINKARBF vs DGROKARBF vs NOBLKARBF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.